Sanofi Faces Charges Over Valproate Birth Defects

French Regulator Planning More Preventive Measures

In a case that has parallels with that of Servier’s diabetes drug Mediator, Sanofi has been indicted over its alleged lack of transparency over the birth defects associated with use of its valproate drug in pregnant women.

Pregnancy_Pills
Sodium valproate caused fetal malformations when used in pregnancy • Source: Shutterstock

More from France

More from Europe